Head-to-head evidence
Camizestrant vs Fulvestrant
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HR+/HER2- Metastatic Breast Cancer
Shared mechanism: Estrogen receptor · full HR+/HER2- Metastatic Breast Cancer pipeline
Camizestrant
Marketed by AstraZeneca
NCT04588298 · Phase 2 · completed
Although participants were randomized among camizestrant dose groups, the study was open-label and had no placebo or active comparator; the primary endpoint was a surrogate biomarker, change in tumor ER expression, rather than a clinical outcome. Reported ER expression decreased across groups, but there was no controlled primary endpoint comparison to establish treatment benefit.
Next expected readout: April 2027 · NCT05774951 (registry estimate)
Fulvestrant · Faslodex
Marketed by AstraZeneca
NCT00635713 · Phase 3 · completed
The trial randomized an estimated 588 participants and used double blinding to compare two active treatment groups: fulvestrant 125 mg plus anastrozole versus fulvestrant 250 mg plus anastrozole. Its primary endpoint was time to tumor progression, a clinical outcome. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: October 2026 · NCT04851613 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Camizestrant's landscape · Fulvestrant's landscape